4502 Takeda Pharmaceutical
- 4173.0
- +77.0+1.88%
Takeda Pharmaceutical News
Takeda Pharmaceutical: 148th Annual General Meeting of Shareholders and Other Electronic Provision Measures
Takeda Pharmaceutical: Takeda Executive Remuneration Overview
Takeda Pharmaceutical: Executive compensation overview
Takeda Pharmaceutical: Message from President and CEO Christophe Weber
Takeda Pharmaceutical: Other items provided electronically at the 148th Annual General Meeting of Shareholders
Takeda Pharmaceutical: Notice of Convocation of the 148th Annual General Meeting of Shareholders and Meeting Materials
Takeda Pharmaceutical: Message from President and CEO Christophe Weber
Takeda Pharmaceutical: Notice of Convocation of the 148th Annual General Meeting of Shareholders and Shareholders' Meeting Materials
Takeda Pharmaceutical: Independent Officer Notification Form
Takeda Pharmaceutical: (Correction) Partial revisions to financial results summary [IFRS] (consolidated) for the fiscal year ending March 31, 2024
Takeda Pharmaceutical: (Correction) Partial correction to the summary of financial statements for the fiscal year ended 2024/3/31 (IFRS, consolidated)
Takeda Pharmaceutical: Continuation of the stock compensation system for our directors and the share grant system for our domestic executives in 2024
Takeda Pharmaceutical: Japan's stock compensation system for directors and share grant system for company managers will continue in 2024
Takeda Pharmaceutical: On the passing of director Olivier Bohuon
Takeda Pharmaceutical: Takeda Pharmaceutical Co., Ltd. sadly announces the passing of Olivier Bohuon director
Takeda Pharmaceutical: Takeda Announces Company-wide Program to Support Growth and Achieve Core Operating Margin Improvement
Takeda Pharmaceutical: About company-wide programs that promote business growth and Core operating margin improvement
Takeda Pharmaceutical: Notice regarding differences between full-year consolidated earnings forecasts and actual values for the fiscal year ending March 31, 2024
Takeda Pharmaceutical: The difference between forecast and actual results for the fiscal year ended March 2024
Takeda Pharmaceutical: Summary of financial statements for the fiscal year ended 2024/3/31 (IFRS, consolidated)
Analysis
Price Target
No Data
